Hyperfine (HYPR) Competitors

NeuroPace (NASDAQ:NPCE) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, community ranking, institutional ownership, risk and dividends.

Does the media prefer NPCE or HYPR?

In the previous week, NeuroPace had 7 more articles in the media than Hyperfine. MarketBeat recorded 18 mentions for NeuroPace and 11 mentions for Hyperfine. NeuroPace's average media sentiment score of 0.64 beat Hyperfine's score of 0.48 indicating that NeuroPace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperfine	0 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is NPCE or HYPR more profitable?

NeuroPace has a net margin of -36.74% compared to Hyperfine's net margin of -309.42%. Hyperfine's return on equity of -57.54% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-36.74%	-205.41%	-28.29%
Hyperfine	-309.42%	-57.54%	-50.38%

Which has higher earnings & valuation, NPCE or HYPR?

NeuroPace has higher revenue and earnings than Hyperfine. NeuroPace is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$71.82M	3.65	-$32.96M	-$1.00	-8.98
Hyperfine	$11.94M	5.38	-$44.24M	-$0.57	-1.55

Do analysts recommend NPCE or HYPR?

NeuroPace currently has a consensus price target of $14.60, indicating a potential upside of 62.58%. Hyperfine has a consensus price target of $1.43, indicating a potential upside of 61.04%. Given NeuroPace's stronger consensus rating and higher possible upside, research analysts plainly believe NeuroPace is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Hyperfine	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the MarketBeat Community prefer NPCE or HYPR?

NeuroPace received 23 more outperform votes than Hyperfine when rated by MarketBeat users. Likewise, 57.45% of users gave NeuroPace an outperform vote while only 44.44% of users gave Hyperfine an outperform vote.

Company	Underperform	Outperform
NeuroPace	Outperform Votes 27 57.45%	Underperform Votes 20 42.55%
Hyperfine	Outperform Votes 4 44.44%	Underperform Votes 5 55.56%

Do insiders & institutionals have more ownership in NPCE or HYPR?

78.8% of NeuroPace shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 22.2% of NeuroPace shares are held by insiders. Comparatively, 29.4% of Hyperfine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more risk and volatility, NPCE or HYPR?

NeuroPace has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500. Comparatively, Hyperfine has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.

Summary

NeuroPace beats Hyperfine on 13 of the 18 factors compared between the two stocks.